Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 3CNS 3NET 2Gastrointestinal 1

Conditions

Neuroendocrine Tumors 7Thyroid Neoplasms 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Thyroid Diseases 2Thyroid Cancer, Papillary 2Thoracic Neoplasms 2Sarcoma 2Salivary Gland Neoplasms 2Respiratory Tract Neoplasms 2Respiratory Tract Diseases 2Pheochromocytoma 2Paraganglioma 2Neuroectodermal Tumors 2Neoplasms, Germ Cell and Embryonal 2Neoplasms by Site 2Neoplasms by Histologic Type 2Neoplasms 2Lung Neoplasms 2Lung Diseases 2Intestinal Neoplasms 2Intestinal Diseases 2Gastrointestinal Neoplasms 2Gastrointestinal Diseases 2Endocrine System Diseases 2Endocrine Gland Neoplasms 2Digestive System Neoplasms 2Colonic Neoplasms 2Colonic Diseases 2

Interventions

lutetium Lu 177 dotatate 1copper dotatate CU-64 1Lutetium-177 1Lutetium 13-Iodobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Pheochromocytoma × NET × Clear all
NCT04711135 2026-02-12

NETTER-P

Advanced Accelerator Applications

Phase 2 Active not recruiting
11 enrolled 14 charts 1 FDA
CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

NCT00874614 2020-02-20

A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Molecular Insight Pharmaceuticals, Inc.

Phase 2 Unknown
74 enrolled 10 charts 1 FDA
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡